News und Analysen
Pharnext Reports First Half 2022 Financial Results
Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer
EQS-News: Burcon NutraScience Corp.: Burcon Announces Annual General Meeting Date
EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022
Form 8.3 - The Vanguard Group, Inc.: PureTech Health plc
Valbiotis Accelerates Its Marketing Strategy
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Valbiotis forciert seine Marketingstrategie
Valbiotis (FR0013254851 – ALVAL, PEA / SME förderfähig), ein Unternehmen für Forschung und Entwicklung, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechsel-
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression
Sensorion to Present at the European Society of Gene & Cell Therapy (ESGCT) and the Gene Therapy for Rare Disorders Europe conferences in October 2022
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.
EQS-Adhoc: Heidelberg Pharma AG Announces Adjustment of Guidance
Pharnext announces a reverse stock split and suspension of the right to exercise all the securities giving access to Pharnext's share capital including the conversions of convertible bonds
Pharnext executes a financing agreement with Néovacs for EUR 20.7 million net to further develop PXT3003 for Charcot-Marie-Tooth disease type 1A
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Valbiotis präsentiert weitere positive Ergebnisse aus der klinischen HEART-Studie zu TOTUM•070 gegen Hypercholesterinämie
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Private Placement of up to EUR 30 Million
Sensorion to Participate in Various Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September 30, 2022
Sensorion Reports 2022 First Half Results
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago
EQS-News: Burcon NutraScience Corp.: Burcon Announces Breakthrough in Sunflower Protein Development